The FDA is beginning rulemaking to close the “adequate provision” loophole
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Maria Soler Nunez appointed as Chief Quality Officer
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Subscribe To Our Newsletter & Stay Updated